Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C29H46N2O3S
CAS Number:
Molecular Weight:
502.75
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Quality level:
Product Name
GW7647, ≥98% (HPLC)
Quality Level
assay
≥98% (HPLC)
color
white
solubility
DMSO: soluble 16 mg/mL, H2O: insoluble
SMILES string
CC(C)(Sc1ccc(CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3)cc1)C(O)=O
InChI
1S/C29H46N2O3S/c1-29(2,27(32)33)35-26-18-16-24(17-19-26)20-22-31(28(34)30-25-14-7-4-8-15-25)21-10-9-13-23-11-5-3-6-12-23/h16-19,23,25H,3-15,20-22H2,1-2H3,(H,30,34)(H,32,33)
InChI key
PKNYXWMTHFMHKD-UHFFFAOYSA-N
Gene Information
human ... PPARA(5465)
Application
GW7647 has been used as a peroxisome proliferator-activated receptor α (PPAR α) ligand:
- in defatting medium to treat primary human hepatocytes
- to test its effect on the glycolytic function in cardiomyocytes
- to test its effect on infant mouse heart
- in breast cancer MDA-MB-231 cells to activate PPARs
Biochem/physiol Actions
GW7647 reduces serum triglyceride levels and enhances hepatic expression of genes associated with β-oxidation. Usage of GW7647 along with metformin in conditions of liver steatosis or injury improves the enzymatic levels of aspartate transaminase (AST) and alanine transaminase (ALT) in serum.
Potent human PPARα agonist. Use to study the biology of PPARα receptor in human cells.
Features and Benefits
This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
Legal Information
Sold for research purposes only under agreement from GlaxoSmithKline
Still not finding the right product?
Explore all of our products under GW7647
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Jun Zhang et al.
Oncotarget, 8(13), 20766-20783 (2017-02-12)
Peroxisome proliferators-activated receptors (PPARα, γ and δ) are potentially effective targets for Type 2 diabetes mellitus therapy. The severe effects of known glitazones and the successfully approved agents (saroglitazar and lobeglitazone) motivated us to study novelly potent PPARs drugs with
Sriram Ramanan et al.
Free radical biology & medicine, 45(12), 1695-1704 (2008-10-15)
Whole-brain irradiation (WBI) can lead to cognitive impairment several months to years after irradiation. Studies on rodents have shown a rapid and sustained increase in activated microglia (brain macrophages) following brain irradiation, contributing to a chronic inflammatory response and a
Yanjie Cheng et al.
Molecular therapy. Nucleic acids, 9, 195-206 (2017-12-17)
Widely varied compounds, including certain plasticizers, hypolipidemic drugs (e.g., ciprofibrate, fenofibrate, WY-14643, and clofibrate), agrochemicals, and environmental pollutants, are peroxisome proliferators (PPs). Appropriate dose of PPs causes a moderate increase in the number and size of peroxisomes and the expression
Global Trade Item Number
| SKU | GTIN |
|---|---|
| G6793-25MG | 04061832954417 |
| G6793-5MG | 04061832954424 |